Borealis was founded on the premise that a convergence of scientific and translational breakthroughs is enabling the field of RNA medicines to treat kidney diseases and beyond. Borealis builds on the success of Chinook Therapeutics, a clinical-stage kidney disease company that was acquired by Novartis in August 2023 for $US3.5 billion. Our team is made up of experienced drug hunters with extensive expertise in kidney disease, targeted delivery of RNA therapeutics, translational systems biology and data sciences, translational biology, chemistry, DMPK and pharmacology.
Chronic kidney diseases are a severe and growing worldwide health challenge that affects 1 in 7 people. Despite recent advances for certain indications such as IgA nephropathy, many forms of highly prevalent kidney diseases do not have effective treatments. As a result, numerous patients can experience kidney failure leading to dialysis and transplantation. We are focused on kidney diseases with large unmet need, with the goal of improving the lives of patients globally.
